PANIC
MCID: PNC025
MIFTS: 52

Panic Disorder (PANIC)

Categories: Mental diseases, Neuronal diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Panic Disorder

MalaCards integrated aliases for Panic Disorder:

Name: Panic Disorder 11 75 53 41 43 14 16 71 33
Episodic Paroxysmal Anxiety Disorder 33
Panic Anxiety Syndrome 11
Panic Disorder 1 71
Panic 53

Classifications:



External Ids:

Disease Ontology 11 DOID:594
MeSH 43 D016584
NCIt 49 C34890
SNOMED-CT 68 191705007
ICD10 31 F41.0
ICD11 33 56162827
UMLS 71 C0030319 C1868649

Summaries for Panic Disorder

MedlinePlus: 41 Panic disorder is a type of anxiety disorder. It causes panic attacks, which are sudden feelings of terror when there is no real danger. You may feel as if you are losing control. You may also have physical symptoms, such as: Fast heartbeat Chest or stomach pain Breathing difficulty Weakness or dizziness Sweating Feeling hot or a cold chill Tingly or numb hands Panic attacks can happen anytime, anywhere, and without warning. You may live in fear of another attack and may avoid places where you have had an attack. For some people, fear takes over their lives and they cannot leave their homes. Panic disorder is more common in women than men. It usually starts when people are young adults. Sometimes it starts when a person is under a lot of stress. Most people get better with treatment. Therapy can show you how to recognize and change your thinking patterns before they lead to panic. Medicines can also help. NIH: National Institute of Mental Health

MalaCards based summary: Panic Disorder, also known as episodic paroxysmal anxiety disorder, is related to panic disorder 1 and anxiety. An important gene associated with Panic Disorder is MIR22 (MicroRNA 22), and among its related pathways/superpathways are Sudden infant death syndrome (SIDS) susceptibility pathways and Monoamine transport. The drugs Methylphenidate and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include heart, amygdala and brain, and related phenotypes are Decreased viability and nervous system

Disease Ontology: 11 An anxiety disorder that is characterized by unexpected and repeated episodes of intense fear accompanied by physical symptoms that may include chest pain, heart palpitations, shortness of breath, dizziness, or abdominal distress.

Wikipedia: 75 Panic disorder is a mental and behavioral disorder, specifically an anxiety disorder characterized by... more...

Related Diseases for Panic Disorder

Diseases in the Panic Disorder family:

Panic Disorder 1 Panic Disorder 2
Panic Disorder 3

Diseases related to Panic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 573)
# Related Disease Score Top Affiliating Genes
1 panic disorder 1 33.4 PAND1 COMT
2 anxiety 32.7 TSPO TPH2 SLC6A4 SLC6A2 PTK7 MAOA
3 agoraphobia 32.4 SLC6A4 SLC6A2 PTK7 MIR22 MAOA HTR2A
4 major depressive disorder 32.3 TSPO TPH2 SLC6A4 SLC6A2 MAOA HTR3A
5 social phobia 31.9 SLC6A4 MAOA HTR3A HTR2A HTR1A CRH
6 generalized anxiety disorder 31.9 TSPO SLC6A4 SLC6A2 MAOA HTR3A HTR2A
7 personality disorder 31.8 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
8 alcohol use disorder 31.8 SLC6A4 MAOA CRH COMT
9 post-traumatic stress disorder 31.8 SLC6A4 MAOA HTR2A HTR1A CRH COMT
10 obsessive-compulsive disorder 31.7 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
11 phobia, specific 31.6 SLC6A4 MAOA HTR1A CRH COMT
12 substance abuse 31.6 SLC6A4 MAOA HTR2A HTR1A CRH COMT
13 separation anxiety disorder 31.6 TSPO SLC6A4 MAOA HTR1A CRH COMT
14 mood disorder 31.5 TPH2 SLC6A4 SLC6A2 MAOA HTR3A HTR2A
15 hypochondriasis 31.5 SLC6A4 MAOA HTR2A HTR1A
16 alexithymia 31.5 SLC6A4 HTR2A CRH COMT
17 dysthymic disorder 31.4 SLC6A4 SLC6A2 MAOA HTR2A HTR1A CRH
18 alcohol dependence 31.4 TSPO TPH2 SLC6A4 MAOA HTR3A HTR2A
19 neurotic disorder 31.4 SLC6A4 MAOA HTR2A HTR1A CRH COMT
20 irritable bowel syndrome 31.3 SLC6A4 HTR3A HTR2A HTR1A CRH COMT
21 acute stress disorder 31.3 SLC6A4 HTR2A CRH
22 endogenous depression 31.2 TPH2 SLC6A4 MAOA HTR2A HTR1A CRH
23 somatization disorder 31.2 SLC6A4 CRH
24 withdrawal disorder 31.2 TSPO SLC6A4 HTR1A CRH
25 bipolar disorder 31.2 TSPO TPH2 SLC6A4 SLC6A2 MAOA HTR3A
26 eating disorder 31.2 SLC6A4 HTR3A HTR2A HTR1A CRH COMT
27 avoidant personality disorder 31.2 SLC6A4 MAOA
28 migraine with or without aura 1 31.1 SLC6A4 MAOA HTR3A HTR2A HTR1A CRH
29 headache 31.1 SLC6A4 HTR3A HTR2A COMT CCK
30 bulimia nervosa 31.0 SLC6A4 MAOA HTR3A HTR2A COMT CCK
31 sleep disorder 31.0 SLC6A4 HTR2A HTR1A CRH COMT
32 substance dependence 31.0 SLC6A4 MAOA HTR2A HTR1A CRH COMT
33 borderline personality disorder 31.0 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
34 psychotic disorder 31.0 TPH2 SLC6A4 MIR22 MAOA HTR3A HTR2A
35 attention deficit-hyperactivity disorder 31.0 TPH2 SLC6A4 SLC6A2 MAOA HTR2A HTR1A
36 obsessive-compulsive personality disorder 31.0 SLC6A4 HTR2A COMT
37 somatoform disorder 30.9 SLC6A4 HTR2A HTR1A CRH COMT
38 fibromyalgia 30.9 TSPO SLC6A4 MAOA HTR3A HTR2A HTR1A
39 cyclothymic disorder 30.9 SLC6A4 HTR2A HTR1A COMT
40 bipolar i disorder 30.9 SLC6A4 HTR2A HTR1A COMT
41 body dysmorphic disorder 30.9 SLC6A4 MAOA HTR2A
42 phobic disorder 30.9 SLC6A4 PTK7 MAOA HTR2A HTR1A CRH
43 tobacco addiction 30.8 SLC6A4 MAOA HTR2A HTR1A CRH COMT
44 amnestic disorder 30.7 TSPO HTR3A HTR1A
45 disease of mental health 30.7 SLC6A4 MIR22 MAOA HTR2A HTR1A CRH
46 premature ejaculation 30.6 SLC6A4 HTR1A COMT
47 paranoid schizophrenia 30.6 SLC6A4 MAOA HTR2A HTR1A COMT
48 drug dependence 30.6 SLC6A4 MAOA CRH COMT
49 schizoaffective disorder 30.6 SLC6A4 HTR2A HTR1A COMT
50 opiate dependence 30.6 SLC6A4 CRH COMT

Graphical network of the top 20 diseases related to Panic Disorder:



Diseases related to Panic Disorder

Symptoms & Phenotypes for Panic Disorder

GenomeRNAi Phenotypes related to Panic Disorder according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.28 SLC6A4
2 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
4 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A

MGI Mouse Phenotypes related to Panic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.1 CCK CCKAR CCKBR COMT CRH HTR1A
2 renal/urinary system MP:0005367 9.86 CCK CCKAR CCKBR COMT CRH HTR3A
3 endocrine/exocrine gland MP:0005379 9.85 CCK CCKAR CCKBR COMT CRH HTR2A
4 cardiovascular system MP:0005385 9.65 CCKBR COMT HTR1A MAOA MIR22 PTK7
5 behavior/neurological MP:0005386 9.47 CCKAR CCKBR COMT CRH HTR1A HTR2A

Drugs & Therapeutics for Panic Disorder

Drugs for Panic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
2
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
3
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
4
Suvorexant Approved, Investigational Phase 4 1030377-33-3 57505028 24965990
5
Promethazine Approved, Investigational Phase 4 60-87-7 4927
6
Duloxetine Approved Phase 4 136434-34-9, 116539-59-4 60835
7
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
8
Norepinephrine Approved Phase 4 51-41-2 439260
9
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
10
Clozapine Approved Phase 4 5786-21-0 2818 135398737
11
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
12
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
13
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
14
Ziprasidone Approved Phase 4 146939-27-7 60854
15
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
16
Sertraline Approved Phase 4 79617-96-2 68617
17
Dexetimide Withdrawn Phase 4 21888-98-2 30843
18 Dopamine Uptake Inhibitors Phase 4
19 Orexin Receptor Antagonists Phase 4
20 Dopamine Agents Phase 4
21 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
22 Analgesics Phase 4
23 Anticonvulsants Phase 4
24 Antipsychotic Agents Phase 4
25 Dopamine Antagonists Phase 4
26 Serotonin Receptor Agonists Phase 4
27 Serotonin 5-HT3 Receptor Antagonists Phase 4
28 Serotonin 5-HT1 Receptor Agonists Phase 4
29
Quetiapine Fumarate Phase 4 111974-72-2
30 Dopamine agonists Phase 4
31 Anti-Anxiety Agents Phase 4
32 Neurotransmitter Agents Phase 4
33 Psychotropic Drugs Phase 4
34 Hypnotics and Sedatives Phase 4
35 GABA Modulators Phase 4
36 Antidepressive Agents Phase 4
37 Serotonin Uptake Inhibitors Phase 4
38
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
39
Venlafaxine Approved Phase 3 99300-78-4, 93413-69-5 5656
40
Risperidone Approved, Investigational Phase 3 106266-06-2 5073
41
Levetiracetam Approved Phase 3 102767-28-2 441341 5284583
42
Cycloserine Approved Phase 3 68-41-7 6234
43
Lecithin Approved, Experimental, Investigational, Nutraceutical Phase 3 8002-43-5, 1446756-47-3, 18656-38-7 26197 9547096 6323481
44
Xenon Experimental Phase 2, Phase 3 7440-63-3
45 Nootropic Agents Phase 3
46 Anesthetics, Inhalation Phase 2, Phase 3
47 Anesthetics, General Phase 2, Phase 3
48 Anesthetics Phase 2, Phase 3
49 Sunflower Phase 3
50 Anti-Bacterial Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 217)
# Name Status NCT ID Phase Drugs
1 Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release Unknown status NCT00492414 Phase 4 Paroxetine CR
2 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Unknown status NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
3 Changes of Cerebral Glucose Metabolism Associated With the Fear Network Activity Before and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4 Lexapro
4 The Role of Orexin in Human Panic Disorder Completed NCT02593682 Phase 4 suvorexant;placebo
5 Phase 4 Study of Panic Disorder That Expresses to Change of Cerebral Glucose Metabolism After 12 Week of Paroxetine Treatment Completed NCT00767754 Phase 4 Paxil CR
6 A Randomized, Controlled Trial on the Effects of Paroxetine Versus Placebo in Combination With Aerobic Exercise or Relaxation Training in the Treatment of Panic Disorder Completed NCT00540098 Phase 4 paroxetine + aerobic exercise;Paroxetine + relaxation;Placebo + aerobic exercise;Placebo + relaxation
7 The Efficacy and Tolerability of Duloxetine for the Treatment of Panic Disorder Completed NCT00438971 Phase 4 Duloxetine
8 A Randomized, Double-Blind, Multicenter Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
9 Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment: a Clinical Randomized Trial Completed NCT00803400 Phase 4 Alprazolam;Alprazolam + Aerobic exercise
10 Combined Treatment With A Benzodiazepine (Clonazepam) And A Selective Serotonin Reuptake Inhibitor (Paroxetine) For Rapid Treatment Of Panic Disorder With Depression Completed NCT00031317 Phase 4 Paroxetine;Clozapine
11 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder Completed NCT00167479 Phase 4 risperidone (Risperdal)
12 A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder Completed NCT02395510 Phase 4 Vortioxetine
13 A Randomized Double-Blind Comparison of Sertraline With Early Alprazolam XR Co-Administration vs Sertraline/Placebo for Primary Care Panic Disorder Patients Completed NCT00198094 Phase 4 Sertraline and Alprazolam XR
14 A Multicenter, Randomized, Open-label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
15 An 8-week, Randomized, Double-Blind, Placebo-Controlled Trial of Seroquel SR Co-administration for SSRI-Resistant, Comorbid Panic Disorder Completed NCT00619892 Phase 4 quetiapine XR;placebo
16 The Effects of Treatment With Sertraline for Panic Disorder and/or Depression Driven Chest Pain and/or Palpitations in a Double Blind, Care as Usual and Placebo Controlled Study Completed NCT01114100 Phase 4 sertraline;placebo
17 Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia Completed NCT02852577 Phase 4 Clonazepam;Paroxetine
18 Randomized Controlled Trial of Escitalopram Versus Placebo for Patients With Irritable Bowel Syndrome and Panic Disorder Completed NCT01551225 Phase 4 Escitalopram
19 Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters Completed NCT00438386 Phase 4 Aripiprazole
20 A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. Completed NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
21 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
22 Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes Completed NCT00347269 Phase 4 Psychotropic medication optimization
23 Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety Completed NCT03522844 Phase 4 Escitalopram
24 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients (MOSAIC) Completed NCT01201967 Phase 4
25 A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder Completed NCT01172652 Phase 4 Ziprasidone;Placebo
26 Pharmacotherapy in Depression With Panic Spectrum Completed NCT00177996 Phase 4 sertraline hydrochloride
27 An Open-label Study to Assess the Safety and Tolerability of Xanax XR in the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks Terminated NCT00634790 Phase 4 alprazolam XR
28 A Randomized, Double-blind, Placebo-controlled Study of Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder Terminated NCT00635531 Phase 4 alprazolam XR
29 A Randomized, Double-blind, Placebo-controlled Study of Continuation Treatment With Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder Terminated NCT00635076 Phase 4 alprazolam XR
30 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
31 Mechanisms of CBT-Treatment Effects in Patients With Panic Disorder and Panic Disorder With Agoraphobia: The Role of Interoceptive Exposure Unknown status NCT01323556 Phase 2, Phase 3
32 Internet- Versus Group-Administered Cognitive Behavior Therapy for Panic Disorder in a Psychiatric Setting: A Randomized Equivalence Trial Completed NCT00845260 Phase 3
33 Treatment Refractory Panic Disorder Completed NCT00118417 Phase 2, Phase 3 Clonazepam;Sertraline
34 A Double-blind, Placebo-controlled, Parallel-group Comparison of Venlafaxine Extended-release Capsules and Paroxetine in Outpatients With Panic Disorder Completed NCT00044772 Phase 3 Venlafaxine ER
35 A Double-blind, Placebo-controlled, Parallel-group, Flexible-dose Study of Venlafaxine Extended-release Capsules in Adult Outpatients With Panic Disorder Completed NCT00038896 Phase 3 Venlafaxine ER
36 Pilot Study of Venlafaxine Extended Release (XR) in the Treatment of Panic Disorder (PD) in Comparison to Paroxetine. Completed NCT00195598 Phase 3 VENLAFAXINE;Paroxetine
37 Dynamic Treatment vs. CBT for Panic Disorder Completed NCT00353470 Phase 3
38 Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks Completed NCT00279617 Phase 3 levetiracetam
39 Randomized Controlled Trial of Psychodynamic Psychotherapy vs. Applied Relaxation for Panic Disorder Completed NCT00128388 Phase 2, Phase 3
40 Treatment of Panic Disorder: Long Term Strategies Completed NCT00000368 Phase 3 Paroxetine or other medication - algorithm used
41 A Randomized, Controlled Study of a Stepped-care Model for the Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
42 Cognitive Behavioral Interventions That Target Personality Risk for Substance Abuse and Mental Illness: Delivery by Educational Professionals Completed NCT00776685 Phase 2, Phase 3
43 The RELAX Trial: Reducing Limitations From Anxiety in Primary Care Completed NCT00158327 Phase 3
44 Improving Quality of Primary Care for Anxiety Disorders Completed NCT00102427 Phase 2, Phase 3
45 A New School-based Drug Prevention Programme for Teenagers: Interventions That Target Personality Risk for Substance Abuse and Mental Illness Completed NCT00344474 Phase 2, Phase 3
46 Online Treatments for Mood and Anxiety Disorders in Primary Care Completed NCT01482806 Phase 2, Phase 3
47 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Concurrent Moderately Severe Anxiety and Lifetime Panic or Generalized Anxiety Disorder Completed NCT00277654 Phase 3 Risperidone
48 Parent-based Treatment for Youth With Anxiety and Obsessive-compulsive Disorder: Comparison of Therapist-Led and Therapist Assisted Approaches Recruiting NCT04922502 Phase 2, Phase 3
49 A Double-Blind, Randomized, Placebo-Controlled Trial of Xenon Inhalation for Treatment of Patients With Panic Disorder Not yet recruiting NCT04432155 Phase 2, Phase 3 Xenon;Placebo
50 Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Not yet recruiting NCT03549819 Phase 3 Cannabidiol (CBD) Oil Capsules;Sunflower Lecithin Oil in Capsule

Search NIH Clinical Center for Panic Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam
Clomipramine
Clomipramine Hydrochloride
Clonazepam
Diazepam
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Maprotiline
Maprotiline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Propranolol
Propranolol Hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam

Cochrane evidence based reviews: panic disorder

Genetic Tests for Panic Disorder

Anatomical Context for Panic Disorder

Organs/tissues related to Panic Disorder:

MalaCards : Heart, Amygdala, Brain, Temporal Lobe, Prefrontal Cortex, Cingulate Cortex, Cortex

Publications for Panic Disorder

Articles related to Panic Disorder:

(show top 50) (show all 16245)
# Title Authors PMID Year
1
The fear of losing control. 62 41
36113905 2022
2
The Bergen 4-day treatment for panic disorder: replication and implementation in a new clinic. 62 41
36418989 2022
3
Patient characteristics and changes in anxiety symptoms in patients with panic disorder: Post-hoc analysis of the PARADIES cluster randomised trial. 62 41
36174096 2022
4
Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 are associated with panic disorder and regulate several anxiety candidate genes and related pathways. 62 46
21168126 2011
5
Gene variations in the cholecystokinin system in patients with panic disorder. 53 62
20023595 2010
6
Platelet serotonin transporter function and heart rate variability in patients with panic disorder. 53 62
20358007 2010
7
Association of a polyadenylation polymorphism in the serotonin transporter and panic disorder. 53 62
19969287 2010
8
The complex global pattern of genetic variation and linkage disequilibrium at catechol-O-methyltransferase. 53 62
18574484 2010
9
Panic disorder is associated with the serotonin transporter gene (SLC6A4) but not the promoter region (5-HTTLPR). 53 62
18663369 2010
10
The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. 53 62
19683026 2009
11
CCK as a modulator of cardiovascular function. 53 62
19563885 2009
12
Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3alpha,5alpha-tetrahydrodeoxycorticosterone concentrations. 53 62
19501468 2009
13
The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects. 53 62
19289240 2009
14
779 TC of CCK-1 intron 1 is associated with postprandial syndrome (PDS) in Japanese male subjects. 53 62
19760980 2009
15
Sympathetic activity relates to adenosine A(2A) receptor gene variation in blood-injury phobia. 53 62
18629431 2009
16
Effects of experimentally induced panic attacks on neuroimmunological markers. 53 62
19023641 2009
17
CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects. 53 62
18562429 2009
18
Functional neuroanatomy of CCK-4-induced panic attacks in healthy volunteers. 53 62
18095276 2009
19
Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4. 53 62
18534623 2009
20
The association between serotonin-related gene polymorphisms and panic disorder. 53 62
18436425 2008
21
Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers. 53 62
18832011 2008
22
Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder. 53 62
18384079 2008
23
Impact of state and trait anxiety on the panic response to CCK-4. 53 62
18414777 2008
24
Influence of the catechol-O-methyltransferase val158met genotype on amygdala and prefrontal cortex emotional processing in panic disorder. 53 62
18440204 2008
25
Platelet 18 kDa Translocator Protein density is reduced in depressed patients with adult separation anxiety. 53 62
18054208 2008
26
Effect of time of preparation on pentagastrin-induced symptom, endocrine and cardiovascular responses. 53 62
18222546 2008
27
Respiratory irregularity and stress hormones in panic disorder: exploring potential linkages. 53 62
17557312 2008
28
Lack of association between the serotonin transporter promoter polymorphism (5-HTTLPR) and personality traits in asymptomatic patients with panic disorder. 53 62
18164547 2008
29
Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. 53 62
17997137 2007
30
Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor. 53 62
17613943 2007
31
Lack of association between the Serotonin Transporter Promoter Polymorphism (5-HTTLPR) and Panic Disorder: a systematic review and meta-analysis. 53 62
17705872 2007
32
Meta-analysis of COMT val158met in panic disorder: ethnic heterogeneity and gender specificity. 53 62
17357147 2007
33
Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. 53 62
17318504 2007
34
Reduced serotonin-1A receptor binding in social anxiety disorder. 53 62
16979141 2007
35
Effects of repetitive transcranial magnetic stimulation (rTMS) on panic attacks induced by cholecystokinin-tetrapeptide (CCK-4). 53 62
16817979 2007
36
Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. 53 62
17035932 2007
37
HPA axis activity in patients with panic disorder: review and synthesis of four studies. 53 62
16845643 2007
38
Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder. 53 62
17123728 2007
39
Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population. 53 62
16822601 2006
40
Association of the Val158Met catechol O-methyltransferase genetic polymorphism with panic disorder. 53 62
16525418 2006
41
The novel brain-specific tryptophan hydroxylase-2 gene in panic disorder. 53 62
16401665 2006
42
Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. 53 62
16600640 2006
43
The neuronal noradrenaline transporter, anxiety and cardiovascular disease. 53 62
16785272 2006
44
Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram. 53 62
16541242 2006
45
Cholecystokinin hyperresponsiveness in functional dyspepsia. 53 62
16718754 2006
46
Evidence that variation in the peripheral benzodiazepine receptor (PBR) gene influences susceptibility to panic disorder. 53 62
16511838 2006
47
Cell-specific repressor or enhancer activities of Deaf-1 at a serotonin 1A receptor gene polymorphism. 53 62
16467535 2006
48
Megestrol attenuates the hormonal response to CCK-4-induced panic attacks. 53 62
16470820 2006
49
Increased prevalence of functional gastrointestinal disorders in panic disorder: clinical and theoretical implications. 53 62
16273019 2005
50
Peripheral-type benzodiazepine receptor binding sites in platelets of patients with panic disorder associated to separation anxiety symptoms. 53 62
15830231 2005

Variations for Panic Disorder

Expression for Panic Disorder

Search GEO for disease gene expression data for Panic Disorder.

Pathways for Panic Disorder

Pathways related to Panic Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1 11.83 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
2
Show member pathways
11.19 MAOA SLC6A2 SLC6A4 TPH2
3
Show member pathways
11.18 TPH2 MAOA COMT
4
Show member pathways
11.01 HTR2A HTR1A CRH
5
Show member pathways
10.9 SLC6A4 MAOA COMT
6 10.88 TPH2 SLC6A4 MAOA HTR3A HTR2A HTR1A
7 10.77 MAOA COMT
8
Show member pathways
10.73 SLC6A4 SLC6A2
9 10.59 MAOA COMT
10 10.54 CCKBR CCK
11
Show member pathways
10.46 TPH2 SLC6A4 SLC6A2 MAOA HTR1A COMT
12 10.13 MAOA COMT

GO Terms for Panic Disorder

Cellular components related to Panic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.64 SLC6A4 SLC6A2 PTK7 HTR3A HTR2A HTR1A
2 plasma membrane GO:0005887 9.64 SLC6A4 SLC6A2 PTK7 HTR3A HTR2A HTR1A

Biological processes related to Panic Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 10.02 CRH HTR1A HTR2A HTR3A SLC6A2
2 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.97 HTR2A CCKBR CCKAR
3 dopamine catabolic process GO:0042420 9.76 MAOA COMT
4 monoamine transport GO:0015844 9.73 SLC6A4 SLC6A2
5 neurotransmitter catabolic process GO:0042135 9.71 MAOA COMT
6 catecholamine metabolic process GO:0006584 9.48 MAOA COMT
7 regulation of hormone secretion GO:0046883 9.46 HTR1A CCKAR
8 behavior GO:0007610 9.37 HTR2A HTR1A
9 neurotransmitter reuptake GO:0098810 9.26 SLC6A4 SLC6A2
10 cholecystokinin signaling pathway GO:0038188 9.26 CCKBR CCKAR
11 serotonin receptor signaling pathway GO:0007210 9.1 HTR3A HTR2A HTR1A

Molecular functions related to Panic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 monoamine transmembrane transporter activity GO:0008504 9.46 SLC6A4 SLC6A2
2 cholecystokinin receptor activity GO:0004951 9.26 CCKBR CCKAR
3 serotonin binding GO:0051378 9.23 SLC6A4 HTR3A HTR2A HTR1A

Sources for Panic Disorder

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....